Guest Speakers

cdifflasvegas

 

 

 

5th Annual
International C. diff. Awareness
Conference & Health EXPO

University of Nevada – Las Vegas
Thomas and Mack Center
4505 Maryland Parkway
Las Vegas, Nevada 89154

Thursday, November 9th    AND     Friday , November 10th
8:00 a.m. – 4:00 p.m.                             8:00 a.m. – 3:00 p.m.

Hotel Accommodations
Getting There
International Visitors
Plan Your Visit
Corporate and Exhibitor Sponsors

 

gerdingphotoDale Gerding, MD, FACP, FIDSA
Dr. Gerding, is the Conference Chair
and Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA.

Dr. Gerding joins fellow world-renowned topic experts to discuss the burden of
C. difficile infections with the risk factors pertaining to current and emerging treatment options along with the importance of applying evidence-based clinical approaches
to the prevention of a C. difficile infection (CDI), one of the leading community and healthcare-associated infections.
Topic:  Non-Toxigenic Clostridium difficile (“NTCD”) technology for the prevention and
treatment of Clostridium difficile infection

Stuart B. Johnson, MD, FIDSA, DTM&H
Dr. Johnson, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus has involved the epidemiology  pathogenesis, and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early recurrences of CDI.
Topic:

simonheadshot-001 Simon M. Cutting, PhD
Professor Cutting of Molecular Microbiology at Royal Holloway, University of London is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus Clostridium difficile.. His other expertise is in the use of Bacillus spores as probiotics and has a number of contracts and consultancies with European and US companies in the food and feed sectors.
Topic: “Thwarting the Opportunist: An Anti-adhesion
Vaccine That Prevents C.difficult Colonization.”

Joseph Sliman, MD, MPH
Dr. Sliman, Chief Medical Officer joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position,  Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives.  During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master’s Degree in Public Health from the Johns Hopkins University School of Public Health, and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University
Topic:

drpaulfeuerstadt Paul Feuerstadt, MD, FACG
Dr. Feuerstadt is a Native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training.His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr. Feuerstadt is affiliated with St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT
Topic:

p1400894 Barley Chironda,, RPN, CIC
Barley Chironda is a Nurse, National Healthcare Sales Director and Infection Control Specialist Clorox Canada, Social Media Manager of IPAC Canada,  Member of the C Diff Global Foundation’s Infection Prevention Advocacy Program,, and the current President of IPAC- GTA.   Mr. Chironda is certified in Infection prevention and control (CIC™) and has worked extensively in Infection Control.  He is typically found engaged in motivating hospital staff, patients and the public on proper infection prevention practices.   Mr. Chironda’s roles allow great participation in quality improvement interventions related to patient and public safety. Therefore Barley has been an integral to the successful decline in Clostridium difficile infections through implementing innovative technology and quality improvement behavioral change.
Topic:

polage_christopher190 Christopher R. Polage, MD
Dr. Polage is Assistant Professor of Clinical Pathology, Director of Clinical Microbiology Laboratory, Department of Pathology and Laboratory Medicine at UC Davis Medical Center.Dr. Polage received a bachelor degree in Biology (1992) and Doctor of Medicine (2000)from the University of New Mexico. Clinical Internship in Internal Medicine at University of Colorado and residency training in anatomic and clinical pathology at the University of Utah receiving an award for research involving the identification of non-fermenting Gram negative bacteria via Amplication and dequencing of 16s rDNA. He stayed in Utah to complete a two year fellowship in Medical Microbiology at ARUP Laboratories, serving as Acting Assistant Medical Director of Mycobacteriology. Dr. Polage’s Clinical Interests are Utilization of laboratory testing for diagnosis of infectious diseases, Diagnosis of viral CNS and respiratory syndromes, Diagnosis of infection in the setting of colonizing microbial flora, Access to laboratory testing and diagnosis in resource-limited settings, Research interests in developing methods to improve the rapidity and clinical impact of infectious disease testing, application of non-culture based methods, identification of markers of pathogenicity, virulence and clinical prognosis.
Topic:

khanna_sahil_13ap-2Sahil Khanna, MD
Dr. Khanna is an Assistant Professor of Medicine in the Division of Gastroenterolgy and Hepatology at Mayo Clinic, Rochester, MN.  His completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at University of California, San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty.  Dr. Khanna has completed Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations.  He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials at the May Clinic, Rochester, MN.
Topic:

MarthaClokieheadshot (2)
Martha Clokie, Ph.D.
Professor Clokie is a Professor of Microbiology at the University of Leicester, UK,  Department of Infection, Immunity, and Inflammation. Professor Cloakie’s primary research interest is in understanding the ecology and molecular biology of bacteriophages and their relationships with bacterial hosts; both in bacterial pathogens and environmentally important bacteria. Much of her work focuses on the exploitation of bacteriophages and phage-derived products as an alternative to treating antibiotic resistant bacterial infections.The system that Professor Cloakie has progressed furthest is Clostridium difficile where her research group has identified a large set of phages that effectively target this pathogen and are currently developing them as therapeutics, Other projects include determining the impact of phages on the gut microbiota.
Topic:

Cliff-McDonald Clifford McDonald, MD,,
Dr. McDonald graduated from Northwestern University Medical School. He completed a medical microbiology fellowship at Duke University and is a former member of CDC’s Epidemic Intelligence Service. Dr. McDonald is currently the Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC. He has first authored or co-authored over 100 peer reviewed publications on subjects related to healthcare and infectious disease epidemiology.
Topic:  “Our Ongoing Battle Against C. diff.: A Status Update, 2017.”

C.diff. SurvivorC. diff. Survivors
Mr. Roy Poole, Mrs. Victoria Edmund, and Mrs. Kathy Bischoff  – each guest is a C. diff. Survivor and join us to share their personal C. difficile infection journey; The signs, symptoms, treatments, with the physical, mental, and psycho-social changes endured from this life-threatening infection and how each recurrent C. difficile infection (rCDI) impacted their lives.
Topic:  “A C. diff. Survivor’s Journey.”

davidcookteam_cook01David Cook, PhD;  Dr. Cook is a scientist and entrepreneur who has held senior operating and management positions in the biotechnology industry over his 20-year career. Before joining Seres Therapeutics, he was the chief operating officer for the International AIDS Vaccine Initiative, a global R&D organization whose mission is to develop a safe, globally accessible vaccine for HIV. Prior to IAVI, David was the founding CEO at Anza Therapeutics, a biotechnology start-up developing a novel microbial vaccine platform to induce cellular immune responses to fight or prevent diseases such as cancer, hepatitis C, malaria and tuberculosis. He is also a co-inventor on over twenty-five patents. He received his undergraduate degree from Harvard College and his PhD in chemistry from the University of California, Berkeley. Dr Cook is presently Executive Vice President of R&D, Chief Scientific Officer with Seres Therapeutics, Inc..
Topic:

 

  • Please check back as we will be adding Guest Speakers to the program agenda weekly

MEDIA INFORMATION:

The C Diff Foundation welcomed members of the Media to the

5th Annual International C. diff. Awareness Conference and Health EXPO

November 9th and 10th, 2017 at the University of Nevada – Las Vegas,

Thomas and Mack Center,  4505 Maryland Parkway,Las Vegas, Nevada 45003

Qualifications and guidelines
Registration is complimentary for professional journalists attending the conference
to provide editorial coverage and who meet the eligibility criteria.

Follow us on Twitter   #Cdiff 2017
@cdiffFoundation